Essec\Faculty\Model\Contribution {#2189
#_index: "academ_contributions"
#_id: "15246"
#_source: array:26 [
"id" => "15246"
"slug" => "a-retrospective-observational-study-of-ibrutinib-in-chronic-lymphocytic-leukaemia-in-a-real-life-setting-in-france-using-the-national-claims-database-osiris"
"yearMonth" => "2024-08"
"year" => "2024"
"title" => "A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)"
"description" => "CHOQUET, S., MARCHAL, C., DEYGAS, F., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G. et LEVY, V. (2024). A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS). <i>Annals of Hematology</i>, 103(8), pp. 2969-2981."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Choquet Sylvain"
]
2 => array:1 [
"name" => "Marchal Clarisse"
]
3 => array:1 [
"name" => "Deygas Floriane"
]
4 => array:1 [
"name" => "Deslandes Marine"
]
5 => array:1 [
"name" => "Macher Nahid"
]
6 => array:1 [
"name" => "Levy Vincent"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-09-30 17:30:33"
"publicationUrl" => "https://doi.org/10.1007/s00277-024-05859-w"
"publicationInfo" => array:3 [
"pages" => "2969-2981"
"volume" => "103"
"number" => "8"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Ibrutinib is a Bruton’s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life."
"en" => "Ibrutinib is a Bruton’s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-10-18T15:22:01.000Z"
"docTitle" => "A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)"
"docSurtitle" => "Journal articles"
"authorNames" => "<a href="/cv/de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>, Choquet Sylvain, Marchal Clarisse, Deygas Floriane, Deslandes Marine, Macher Nahid, Levy Vincent"
"docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard, Choquet Sylvain, Marchal Clarisse, Deygas Floriane, Deslandes Marine, Macher Nahid, Levy Vincent</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2024</span>"
"keywordList" => ""
"docPreview" => "<b>A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)</b><br><span>2024-08 | Journal articles </span>"
"docType" => "research"
"publicationLink" => "<a href="https://doi.org/10.1007/s00277-024-05859-w" target="_blank">A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)</a>"
]
+lang: "en"
+"_type": "_doc"
+"_score": 8.567657
+"parent": null
}
